Cytosorbents Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytosorbents Corporation on February 22, 2011, reporting events occurring on February 15, 2011. The filing details the entry into a material definitive agreement involving the issuance of debt securities to accredited investors.
Key Financial Metrics
The filing does not provide standard operating metrics such as revenue, profit, cash flow, or margins. The primary financial data relates to a new financing transaction:
- Principal Amount: $1,250,000 in Convertible Notes.
- Interest Rate: 8% per annum.
- Maturity Date: February 15, 2013.
- Repayment Method: Repayment in equity (Common Stock) rather than cash.
- Conversion Price: $0.10 per share.
Material Changes and Transaction Details
The Company issued Convertible Notes and associated warrants to certain accredited investors. Key terms include:
- Conversion Rights: Investors may convert principal and accrued interest into Common Stock at $0.10 per share at any time during the term.
- Warrant Coverage: Investors received 100% warrant coverage with a five-year term. The warrants are structured in three tranches with exercise prices of $0.10 (covering 50% of principal), $0.125 (covering 25% of principal), and $0.15 (covering 25% of principal). Warrants include a cashless exercise provision.
- Exchange Rights: If the Company completes a subsequent financing of $750,000 or more, investors have the option to exchange their notes into the new financing.
- Right of First Refusal: If the Company conducts an equity financing of less than $750,000 that values the Company at $35 million or less (pre-money, fully-diluted), investors have a right of first refusal to participate.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on operations, or specific risk factors beyond the terms of the agreement. The securities were issued in reliance on exemptions from registration under Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D. The underlying Common Stock is restricted, and holders do not have registration rights.
Investor Verification Checklist
- Verify the total number of shares issuable upon conversion of the $1,250,000 principal at $0.10 per share.
- Confirm the total number of shares issuable under the warrant tranches and the impact of the cashless exercise provision.
- Assess the dilution impact on existing shareholders given the low conversion and exercise prices.
- Review the Company's current cash position to understand the necessity of equity-repayable debt.
- Check for any subsequent financings that may trigger the exchange rights or right of first refusal.